Indazole compounds, pharmaceutical compositions and use
US4997844A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Oct 18, 1985 |
| Grant date | Mar 5, 1991 |
| Priority date | — |
| Expiry date | Oct 18, 2005 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D409/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention provides a series of novel heterocyclic amides of the formula I in which the group A CRa can be --CRb.dbd.CRa--, --CHRb--CHRa-- or --N.dbd.CRa--, the amidic group Re.L can be Re.X.CO.NH, Re.X.CS.NH or Re.NH.CO attached at position 4, 5 or 6 of the benzenoid moiety, Z is an acid group selected from the group consisting of carboxy, an acylsulphonamide residue of the formula CO.NH.SO.sub.n Rg and a tetrazolyl residue of the formula II, and the radicals Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, n, X, G.sup.1, Q and G.sup.2 have the meanings defined in the following specification. The compounds of formula I are leukotriene antagonists. The invention also provides pharmaceutically acceptable salts of the formula I compounds; pharmaceutical compositions containing the formula I compounds, or their salts, for use in the treatment of, for example, allergic or inflammatory diseases, or endotoxic or traumatic shock conditions; and processes for the manufacture of the formula I compounds, as well as intermediates for use in such manufacture.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.